IRVINE, Calif., March 1, 2017 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), a global market leader in the aesthetic medical device marketplace, will unveil expansions of technologies during the 2017 American Academy of Dermatology (AAD) meeting in Orlando, Fla. The advancements clearly demonstrate Syneron Candela's commitment to providing innovative treatment solutions for various skin and body conditions in the aesthetic and wellness marketplace.
- GentleTouch, a state-of-the-art, solid-state laser system adds CE mark approval to the FDA clearance and joins the Company's portfolio as the first and only device to combine Alexandrite and radiofrequency energies to remove hair safely. Equipped with three operating modes, GentleTouch ensures all hair removal treatments are customizable to the particular needs of each patient. The system additionally includes EverCool, a unique, patent-pending, contact-cooling method and is cleared for hair removal on all skin types (Fitzpatrick I-VI).
- PicoWay, a leading solution for tattoo removal and treatment of benign, pigmented lesions, received FDA clearance for the treatment of acne scars in Fitzpatrick Skin Types II-V for the Resolve holographic 1064 nm wavelength handpiece. By targeting acne scars with high peak power and the shortest pulses available at that wavelength, PicoWay Resolve quickly and effectively treats the appearance of acne scars with minimal patient downtime and side effects.
- UltraShape Power, the first and only non-invasive fat reduction system that uses pulsed, focused ultrasound, will be featured as the newest addition to the body contouring portfolio. When compared to the prior version of UltraShape, the UltraShape Power features a 20% increase in ultrasound power delivered to tissue and an average treatment time of 30 minutes for a typical abdomen. The FDA clinical study demonstrated more than a 30% reduction in fat thickness following a three session treatment protocol.
- Profound, recently FDA cleared to improve the appearance of cellulite, is a minimally invasive, fractional radiofrequency microneedling device. Specifically, the 25º Dermal handpiece and cartridge are used for percutaneous treatment of facial wrinkles, and the 75º SubQ handpiece and cartridge are used to improve the appearance of cellulite in patients with Fitzpatrick Skin Types I-III as supported by long-term clinical data.
"Clinical data to support the efficacy of new products, new indications and safety of our current and new portfolios will continue to be a focus of Syneron Candela," says Philippe Schaison, CEO of Syneron Candela, North America. "Recent advancements of UltraShape Power, GentleTouch, PicoWay and Profound illustrate Syneron Candela's dedication to finding innovative solutions for a variety of patients' aesthetic needs."
Visit the Syneron Candela booth #2953 at the AAD annual meeting to learn more.
About Syneron Candela:
Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, women's intimate health, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company has a wide portfolio of trusted, leading products including UltraShape Power, VelaShape, CO2RE, CO2RE Intima, GentleLase, VBeam Perfecta, PicoWay, Profound and elōs Plus.
Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Candela are located in Israel. Syneron Candela also has R&D and manufacturing operations in the U.S. The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, market acceptance of new products, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and in the filings that Syneron Medical makes with the SEC, and other factors beyond the Company's control. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from those expressed or implied by these forward-looking statements. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
For additional information, please visit http://www.syneron-candela.com.
Heidi Donato, Cohn & Wolfe
Investor Relations contact:
Zack Kubow, The Ruth Group
SOURCE Syneron Candela